Broad spectrum matrix metalloproteinase inhibitors: An examination of succinamide hydroxamate inhibitors with P1 C(α) gem-disubstitution

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 12, 1998, Pages 1443-1448

  Curtin, Michael L ^a   Garland, Robert B ^a   Davidsen, Steven K ^a   Marcotte, Patrick A ^a   Albert, Daniel H ^a   Magoc, Terrance J ^a   Hutchins, Charles ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; HYDROXAMIC ACID DERIVATIVE; MATRIX METALLOPROTEINASE INHIBITOR; SUCCINIMIDE;

ANGIOGENESIS; ARTICLE; BASEMENT MEMBRANE; BIOAVAILABILITY; CONFORMATIONAL TRANSITION; DRUG DISTRIBUTION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HYDROLYSIS; NONHUMAN;

ANIMALS; HYDROXAMIC ACIDS; METALLOENDOPEPTIDASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; RATS;

EID: 0032537578     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00255-8     Document Type: Article

References (13)

1. 1. Birkedal-Hansen, H.; Moore, W. G. I.; Bodden, M. K.; Windsor, L. J.; Birkedal-Hansen, B.; DeCarlo, A.; Engler, J. A. Crit. Rev. Oral Biol. Med. 1993, 4, 197.
2. 2. (a) For a current discussion of potential therapeutic targets, see: White, A. D.; Bocan, T. M. A.; Boxer, P. A.; Peterson, J. T.; Schrier, D. Current Pharm. Design 1997, 3, 45.
3. (b) For a review of MMPs and the development of cancer, see: Coussens, L. M.; Werb, Z. Chem. Biol. 1996, 3, 895.
4. 3. For a recent summary of these and other MMP inhibitors, see: Zask, A.; Levin, J. I.; Killar, L. M.; Skotnicki, J. S. Current Pharm. Design 1996, 2, 624.
5. 4. For one example of reductive metabolism, see: Knebel, N. G.; Sharp, S. R.; Madigan, M. J. J. Chromatography, B: Biomedical Appl. 1995, 213.
6. 5. Robinson, R. P.; Ragan, J. A.; Cronin, B. J.; Donahue, K. M.; Lopresti-Morrow, L. L.; Mitchell, P. G.; Reeves, L. M.; Yocum, S. A. Bioorg. Med. Chem. Lett. 1996, 6, 1719.
7. 6. Beckett, R. P.; Crimmin, M. J.; Davis, M. H.; Spavold, Z. Synlett 1993, 137.
8. 7. The stereochemical assignments of succinates 6 and 7 were based on the work in ref 6.
9. 8. Attempts at making the three- and four-membered gem-cycloalkyl succinates were unsuccessful using several different synthetic approaches.
10. 13C NMR, mass spectroscopy, elemental analysis and optical rotation.
11. 50 values for all compounds except 2 (n = 53) are from a single determination.
12. 11. For a recent discussion of a series of succinamide inhibitors selective for MMP-2 and MMP-3 over MMP-1, see: Esser, C. K.; Bugianesi, R. L.; Caldwell, C. G.; Chapman, K. T.; Durette, P. L.; Girotra, N. N.; Kopka, I. E.; Lanza, T. J.; Levorse, D. A., MacCoss, M.; Owens, K. A.; Ponpipom, M. M.; Simeone, J. P.; Harrison R. K.; Niedzwiecki, L.; Becker, J. W.; Marcy, A. I.; Axel, M. G.; Christen, A. J.; McDonnell, J.; Moore, V. L.; Olszewski, J. M.; Saphos, C.; Visco, D. M.; Shen, F.; Colletti, A.; Krieter, P. A.; Hagmann, W. K. J. Med. Chem. 1997, 40, 1026.
13. 12. Becker, J. W.; Marcy, A. I.; Rokosz, L. L.; Axel, M. G.; Burbaum, J. J.; Fitzgerald, P. M. D.; Cameron, P. M.; Esser, C. K.; Hagmann, W. K.; Hermes, J. D.; Springer, J. P. Protein Sci. 1995, 4, 1966.